HR 1632 · in committee · significant
Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025
- healthcare
What this bill does
- Creates a faster approval process for drugs and medical devices already approved in other countries when there's an unmet medical need.
- Affects pharmaceutical companies, device makers, patients seeking access to treatments, and the FDA.
- FDA must decide within 30 days; Congress can override FDA denials through joint resolution.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How should regulators balance faster access to treatments against the time needed to verify safety data from foreign approvals?
- 02
What safeguards could prevent manufacturers from bypassing rigorous FDA review while still helping patients with unmet medical needs?
- 03
If Congress can override FDA denials, how might this change the FDA's role and what accountability would apply to congressional decisions?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-TX-21
Chip Roy
Citizen cosponsors
0
In Congress
1/ 435
House Reps cosponsoring
Introduced 2025-02-26
Joining the bill
Legislative timeline
2025-02-26 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-26 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-26 · IntroReferral
Introduced in House
2025-02-26 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.